Age-Related Macular Degeneration is one of the leading causes of blindness among seniors, affecting approximately 2.1 million people nationwide[1]. By 2050, it is expected that the number will more than double to 5.4 million[2]. People …
Age-related Macular Degeneration
ARIS
Age-Related Macular Degeneration Ryan Initiative Study (ARIS)
AREDS2
Age-Related Eye Disease Study 2 (AREDS2) 10-Year Follow-On Study
CHROMA
A Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration.